Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Atossa Therapeutics, Inc. (ATOS)

    2.3500 +0.1800 (+8.37%)
    As of 9:46:59 AM EST. Market Open.
    Loading Chart for ATOS
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

    Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
    PR Newswire 14d ago
    Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

    Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
    PR Newswire 24d ago
    Atossa plans shareholder stake in potential PRV proceeds

    Atossa plans shareholder stake in potential PRV proceeds
    Pharmaceutical Technology 1mo ago
    Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

    Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
    PR Newswire 1mo ago
    Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

    Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
    PR Newswire 1mo ago
    Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

    Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
    PR Newswire 2mo ago
    Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

    Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
    PR Newswire 3mo ago
    Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

    Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
    PR Newswire 3mo ago
    ATOS: Raises up to $16.5 Million in Registered Direct Offering

    ATOS: Raises up to $16.5 Million in Registered Direct Offering
    Zacks Small Cap Research 4mo ago
    Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

    Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
    PR Newswire 4mo ago
    Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

    Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
    PR Newswire 4mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: